Ofev is the brand name for the drug nintedanib, a small‑molecule tyrosine‑kinase inhibitor used mainly to slow the progression of idiopathic pulmonary fibrosis (IPF) and some forms of interstitial lung disease.
Because Ofev was first approved in 2015, it’s already entered the generic market, so you can buy it at a lower price point if you’re not on a plan that covers the brand. Below is a quick rundown of the generic and what you need to know if you’re considering it.
1. What is the generic name?
- Generic name: Nintedanib
- Trade names (US): Nintedanib, Nintendanib (some manufacturers use different brand names but the active ingredient is the same).
- Formulations: Oral capsules; 150 mg and 300 mg doses are available (the 150 mg dose is the one used for IPF).
2. How does the generic compare to the brand‑name Ofev?
| Feature |
Ofev (brand) |
Generic nintedanib |
| Active ingredient |
150 mg nintedanib |
150 mg nintedanib |
| Excipient composition |
Slightly different inactive ingredients (but all are FDA‑approved) |
Similar excipients; differences are generally not clinically significant |
| Efficacy |
Proven in pivotal trials |
Same chemical and pharmacokinetic profile – no difference in efficacy |
| Safety profile |
Same as generic |
Same as brand |
| Cost |
$7,500–$8,000/month (average) |
40‑70% lower; check pharmacy for exact price |
| Insurance coverage |
Often covered as preferred brand |
Usually covered under the generic tier, which may lower out‑of‑pocket costs |
Because the generic has the same active ingredient and identical pharmacology, the clinical outcomes should be the same.
3. When might you want to use the generic?
- Cost savings: Most patients can save $3,000–$4,000 per month, or more if they’re on high‑deductible plans.
- Insurance formulary: Many plans list nintedanib as a generic or a lower‑tier brand, so you get a better co‑pay or coinsurance.
- Availability: If your pharmacy runs out of Ofev, the generic may be available sooner.
4. How to get the generic
- Ask your prescriber – They can prescribe the generic if it’s available in your region.
- Check your pharmacy’s formulary – Most community and hospital pharmacies list nintedanib under the generic name.
- Use a discount card – Some drug‑price‑comparison sites or cards can further reduce costs.
- Look for patient assistance programs – The manufacturer of Ofev offers a patient assistance program, and the generic manufacturer may also have similar programs.
5. Safety and Side‑Effect Profile (generic = brand)
| Common Side Effect |
Incidence |
Management |
| Diarrhea |
60–70 % |
Oral rehydration, loperamide; consider dose adjustment if persistent |
| Nausea, vomiting |
30–40 % |
Anti‑emetics; take with food |
| Hepatic enzyme elevation |
5–10 % |
Monitor LFTs monthly in first 3 months |
| Gastro‑intestinal bleeding |
<5 % |
Avoid NSAIDs, antiplatelet drugs (unless essential) |
| Weight loss |
15 % |
Dietitian referral; monitor BMI |
If you notice severe GI bleeding, sudden weight loss, or a persistent high fever, contact your doctor immediately.
6. Drug interactions (generic or brand)
- Cytochrome P450 (CYP) inhibitors/inducers: Nintedanib is metabolized mainly by CYP3A4. Strong inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) can alter levels.
- Anticoagulants: Nintedanib may increase bleeding risk; avoid concurrent anticoagulants if possible.
- Other tyrosine‑kinase inhibitors: Concomitant use may increase adverse events.
- Antacids: Can reduce absorption if taken together – separate timing by at least 4 hours.
Always inform your prescriber of all medications and supplements.
7. Dosage (generic)
- Standard IPF dose: 150 mg orally, twice daily, taken with food.
- Other indications (e.g., progressive fibrosing ILDs) may use the same 150 mg BID regimen.
- If GI side‑effects are intolerable: Start with 75 mg BID, then titrate up to 150 mg BID after 4–6 weeks.
8. Monitoring
| Test |
Frequency |
Why |
| LFTs (AST, ALT, bilirubin) |
Every 4 weeks first 3 months, then every 3 months |
Detect hepatotoxicity |
| CBC |
Every 4 weeks first 3 months |
Look for anemia or thrombocytopenia |
| Weight/BMI |
Each visit |
Monitor for weight loss |
| Pulmonary function tests (PFTs) |
Every 3 months |
Track lung function improvement |
9. FAQ
| Question |
Answer |
| Is the generic as safe as Ofev? |
Yes – it contains the identical active molecule and has been evaluated for bioequivalence. |
| Can I switch from Ofev to generic mid‑treatment? |
Yes, you can, but make sure the prescriber writes a new prescription for the generic. |
| Do I need a new insurance authorization? |
Usually not; most plans treat generics under the same therapeutic class. |
| Will my insurance cover the generic? |
Most will. If your plan has a “preferred generic” tier, you may have a lower copay. |
| Can I get a discount card for the generic? |
Many pharmacies and drug‑price‑comparison sites offer discount cards for nintedanib. |
Bottom line
The generic version of Ofev, nintedanib, provides the same therapeutic benefit for IPF and related fibrotic lung diseases, but at a lower cost. If cost is a barrier, talk to your prescriber about switching to the generic, and double‑check your insurance formulary. And, as always, monitor for GI side‑effects and liver enzymes, especially during the first few months of therapy.
Happy to answer more questions—just let me know!